Lantern Pharma (LTRN) Non-Current Assets (2019 - 2026)
Lantern Pharma's (LTRN) quarterly Non-Current Assets came in at $165807.0 in Q1 2026, down 39.26% YoY from $272959.0 in Q1 2025, and down 28.73% on a QoQ basis from $232639.0 in Q4 2025.
Lantern Pharma (LTRN) Non-Current Assets (2019 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 8 years of Non-Current Assets data on file, last reported at $165807.0 in Q1 2026.
- Quarterly Non-Current Assets fell 39.26% year-over-year to $165807.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $783753.0 (down 38.03% YoY) and the FY2025 annual result came in at $232639.0, down 28.23% from the prior year.
- Non-Current Assets slipped to $165807.0 in Q1 2026, from $232639.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $739359.0 in Q1 2022 to a low of $113584.0 in Q4 2022.
- A 5-year average of $317877.8 and a median of $295352.0 in 2024 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 3566.73% in 2022, down 90.8% in 2022.
- Tracing LTRN's Non-Current Assets over 5 years: stood at $113584.0 in 2022, then surged by 169.66% to $306291.0 in 2023, then gained by 5.83% to $324163.0 in 2024, then slipped by 28.23% to $232639.0 in 2025, then slipped by 28.73% to $165807.0 in 2026.
- The last three Non-Current Assets figures came in at $165807.0 (Q1 2026), $232639.0 (Q4 2025), and $165805.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Lantern Pharma | 26.11 Mn | 26.11 Mn | - | 165,807.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 165,807.00 |
| Dec 31, 2025 | 232,639.00 |
| Sep 30, 2025 | 165,805.00 |
| Jun 30, 2025 | 219,502.00 |
| Mar 31, 2025 | 272,959.00 |
| Dec 31, 2024 | 324,163.00 |
| Sep 30, 2024 | 372,304.00 |
| Jun 30, 2024 | 295,352.00 |
| Mar 31, 2024 | 263,363.00 |
| Dec 31, 2023 | 306,291.00 |
| Sep 30, 2023 | 345,527.00 |
| Jun 30, 2023 | 384,074.00 |
| Mar 31, 2023 | 341,755.00 |
| Dec 31, 2022 | 113,584.00 |
| Sep 30, 2022 | 144,620.00 |
| Jun 30, 2022 | 716,818.00 |
| Mar 31, 2022 | 739,359.00 |
| Dec 31, 2021 | 1.23 Mn |
| Sep 30, 2021 | 1.27 Mn |
| Jun 30, 2021 | 300,990.00 |